Adjusting Overall Survival Estimates for Treatment Switching in Metastatic, Castration-Sensitive Prostate Cancer: Results from the LATITUDE Study

BACKGROUND: LATITUDE was the first phase 3 trial examining the survival benefit of adding abiraterone acetate (AA) + prednisone (P) to androgen-deprivation therapy (ADT) in newly diagnosed metastatic, castration-sensitive prostate cancer (mCSPC). Due to significant improvement in overall survival af...

Descripción completa

Detalles Bibliográficos
Autores principales: Feyerabend, Susan, Saad, Fred, Perualila, Nolen Joy, Van Sanden, Suzy, Diels, Joris, Ito, Tetsuro, De Porre, Peter, Fizazi, Karim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875513/
https://www.ncbi.nlm.nih.gov/pubmed/31754962
http://dx.doi.org/10.1007/s11523-019-00685-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875513/
https://www.ncbi.nlm.nih.gov/pubmed/31754962
http://dx.doi.org/10.1007/s11523-019-00685-x

Ejemplares similares